Queen Mary University of London, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London, UK.
Mol Cell Endocrinol. 2013 May 22;371(1-2):195-200. doi: 10.1016/j.mce.2012.12.010. Epub 2012 Dec 29.
Familial Glucocorticoid deficiency (FGD), in which the adrenal cortex fails to produce glucocorticoids, was first shown to be caused by defects in the receptor for ACTH (MC2R) or its accessory protein (MRAP). Certain mutations in the steroidogenic acute regulatory protein (STAR) can also masquerade as FGD. Recently mutations in mini chromosome maintenance-deficient 4 homologue (MCM4) and nicotinamide nucleotide transhydrogenase (NNT), genes involved in DNA replication and antioxidant defence respectively, have been recognised in FGD cohorts. These latest findings expand the spectrum of pathogenetic mechanisms causing adrenal disease and imply that the adrenal may be hypersensitive to replicative and oxidative stresses. Over time patients with MCM4 or NNT mutations may develop other organ pathologies related to their impaired gene functions and will therefore need careful monitoring.
家族性糖皮质激素缺乏症(FGD)是指肾上腺皮质不能产生糖皮质激素,其最初被认为是由促肾上腺皮质激素(ACTH)受体(MC2R)或其辅助蛋白(MRAP)的缺陷引起的。某些类固醇生成急性调节蛋白(STAR)的突变也可能伪装成 FGD。最近,在 FGD 队列中发现了迷你染色体维持缺陷 4 同源物(MCM4)和烟酰胺核苷酸转氢酶(NNT)的突变,这两个基因分别参与 DNA 复制和抗氧化防御。这些最新发现扩展了导致肾上腺疾病的发病机制谱,并暗示肾上腺可能对复制和氧化应激过度敏感。随着时间的推移,具有 MCM4 或 NNT 突变的患者可能会出现与受损基因功能相关的其他器官病理学,并因此需要仔细监测。